Functional consequences of stem and progenitor cell heterogeneity

总体项目摘要 该计划汇集了五名造血研究人员，他们一直在合作， 解决了个体造血干细胞和祖细胞（HSPC）是如何被 在体内平衡和压力条件下，调节以促进血液的产生。它创造了一个 在研究者的实验室中开发的用于跟踪单个克隆的互补技术的集合 从而模拟不同的克隆行为如何在不同的条件下促进造血输出。 条件此外，它采用创新的工具来操纵基因的特定分子调节因子， 表达以测试哪些分子驱动特定HSPC行为。这些都是测试的背景下， 炎症和遗传毒性应激，并评估其改变 正常HSPC与携带已知在老年人中积累的血液疾病相关等位基因的克隆。 模型、种属、发育时间和分子参数（mRNA，meDNA， ncRNA，染色质状态）通过已建立的公共数据库和分析工具共享， 这是一种独特的强大手段，可以高分辨率地定义造血过程。通过提供 维持互动、分享数据和技术以及建立解决冲突论坛的机制 数据，该PO1将有助于创建造血“路线图”， 分子途径点可以调节血细胞产生，以增强造血再生和限制 疾病环境中异常的克隆生长。

OVERALL PROJECT SUMMARY This program brings together five hematopoiesis investigators who have been working collaboratively to address the fundamental question of how individual hematopoietic stem and progenitor cells (HSPC) are regulated to contribute to the production of blood under homeostatic and stress conditions. It creates a collective of complementary technologies developed in the investigator's laboratories to track individual clones in vivo and thereby to model how distinct clonal behaviors contribute to hematopoietic output under varying conditions. Furthermore, it employs innovative tools for manipulating specific molecular regulators of gene expression to test which molecules drive specific HSPC behaviors. These are tested in the context of inflammatory and genotoxic stress and are evaluated for their ability to alter the competitive relationship of normal HSPC with clones bearing blood disease associated alleles known to accumulate in the aging human. The cross comparison of models, species, time in development and molecular parameters (mRNA, meDNA, ncRNA, chromatin state) shared through an established common database and analytic tools provide a uniquely powerful means of defining with high resolution the process of hematopoiesis. By providing a mechanism to sustain interaction, share data and techniques and create a forum for resolution of conflicting data, this PO1 will facilitate the creation of a hematopoiesis `roadmap' whereby interventions at specific molecular waypoints can modulate blood cell production to enhance hematopoietic regeneration and limit aberrant clonal outgrowth in settings of disease.